NHSL1

Across TCGA pan-cancer cohorts, NHSL1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NHSL1 data layer compared with 17 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher NHSL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NHSL1 expression acts as an unfavorable survival marker, although some lineages such as READ show a favorable association.

CESC, LIHC, and ACC are the cancer types where NHSL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.117	0.587	.034	18	view →
LIHC	OS	Median	II,III,IV	0.010	0.697	<.001	12	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
READ	DFS	Median	II,III,IV	1.000	0.472	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NHSL1–CESC (OS)

Open the CESC breakdown →